This study is for patients who have non-small cell lung cancer that is stage IV or has returned after remission. The goal is to compare the usual treatment by itself to the usual treatment plus a drug called cemiplimab. "Investigational" means this drug combination has not been approved by the U.S. Food and Drug Administration (FDA). A computer will randomly assign patients to one of two groups. This process is called "randomization." Patients will be placed into a group by chance, like flipping a coin, and will have an equal chance of being in Group 1 or Group 2. The drug is given by infusion. Patients will keep getting treatment until the cancer gets worse. Each treatment cycle lasts 21 days. After the last cycle, patients will be followed for up to 3 years.

Genicular Artery Embolization (GAE) is a newer treatment aimed at reducing knee pain caused by osteoarthritis by targeting and reducing inflammation. In people with knee osteoarthritis, inflammation in the joint leads to the growth of tiny new blood vessels, called neovessels. These vessels are not normally present in a healthy joint and contribute to ongoing inflammation and pain.

GAE works by selectively injecting tiny particles into specific arteries that supply blood to these abnormal vessels. This process is called embolization, and it temporarily blocks the flow of blood through the neovessels.

Doctors use a special imaging technique called angiography to guide the procedure. This allows them to see the inflamed area and locate the neovessels, which are larger than normal due to the ongoing inflammation—usually about 1–2 millimeters in diameter.

By blocking these abnormal vessels, GAE helps to reduce the number of inflammatory cells and signaling chemicals (called cytokines) that enter the joint through the bloodstream. This decreases the overall inflammation in the area.

Additionally, the growth of pain-sensing nerves, which often occurs alongside these new vessels, may also be reduced. These nerves—called unmyelinated sensory nerves—can worsen pain when they are activated by inflammation. By decreasing both inflammation and nerve growth, GAE may significantly reduce knee pain in people with osteoarthris

The FDA has not currently approved the study device. Patients will undergo 8 visits over a 12 month period. screening, screening 2,treatment, 30 day follow up,90 days,180,270,365 follow up.

This study is being done to learn more about the study drug pelacarsen (TQJ230) in people with atherosclerotic cardiovascular disease (ASCVD) and elevated Lp(a) and LDL-C levels who are already taking a medication called inclisiran for the treatment of elevated LDL-C. ASCVD refers to the build up of plaques in the blood vessels that can block blood flow and increase the risk of events like heart attacks, strokes or other blood vessel blockages. LDL-C stands for low density lipoprotein cholesterol which is often referred to as bad cholesterol. Pelacarsen is considered investigational meaning it has not yet been approved by the Food and Drug Administration (FDA). This is a randomized study meaning you will be assigned by chance, like the flip of a coin, to receive the study drug or placebo. You have a 1 in 2 chance (50%) of receiving the study drug. Inclisiran is an FDA approved medication to lower LDL-C. The study drug is given as a monthly injection under the skin. This study will last about 21 months and include about 14 visits.

This study aims to create a long-term Ehlers-Danlos syndrome (EDS) biorepository and clinical research database to support gene and biomolecular discovery. The repository will serve as a sustainable resource for advancing EDS-related research by collecting both clinical data and biological samples. Participants who consent will be included in the EDS registry, which stores demographic and operative information, contact details, and biological specimens for current and future studies. Enrolled patients may also choose to be recontacted for future research opportunities. The database will link participants across specialties using identifiers such as name, date of birth, and medical record number. Data collected will include information from electronic health records, such as clinical notes, diagnoses, medications, labs, imaging, anthropometric measures, and procedure reports.

To evaluate safety and performance of the Serranator® in treatment of peripheral artery disease (PAD), or dysfunctional native or synthetic arteriovenous dialysis fistulae (access sites used for dialysis) in a real-world scenario.

This study examines whether adding brief guided mindfulness exercises to accelerated Transcranial Magnetic Stimulation (TMS) treatment can help people with depression feel better and maintain those improvements longer. Participants will already be receiving accelerated intermittent theta-burst stimulation (aiTBS) as part of their clinical care. During the breaks between TMS sessions, they will have the option to listen to short, app-based mindfulness practices using the commercially available and free Healthy Minds App. We will track whether this combined approach is practical, how easy participants find the meditations, and whether practicing mindfulness during treatment improves mood, well-being, or long-term recovery. The information gathered will help us design a larger study focused on improving the durability of TMS outcomes.

This study aims to explore the prevalence of mental health symptoms, including trauma exposure and posttraumatic stress symptoms in a postpartum population. The study also aims to collect information related to medical and mental health treatment seeking before, during, and after pregnancy as well as feedback on adaptations of future mental health interventions delivered during the postpartum period. Participation in this study includes a 35 minute online survey with questionnaires related to the study aims. Depending on survey responses, participants may be invited to complete an interview with study personnel to provide more specific insight on mental health treatments for perinatal individuals.

This Phase 3 study evaluates the safety and efficacy of tapinarof cream, 1%, for treating atopic dermatitis (AD) in pediatric participants aged 3 to under 24 months. Previous research, including two Phase 3 pivotal studies and a long-term study, assessed the cream in adults and children as young as 2 years. These studies showed minimal to no systemic exposure in children aged 2 to 17 with extensive AD. The findings support investigating the cream's safety and efficacy in younger participants, specifically infants and toddlers.

This study will recruit adults diagnosed with an oral potentially malignant disorder (OPMD). The purpose of this research study is to collect blood, saliva, and tissue samples to determine whether certain measurable characteristics (biomarkers) can be identified which may provide insight into the risk of developing cancer. Participation in this study is expected to last approximately 3 years.

Co-occurring post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) disproportionately affects Veterans and has significant negative impacts on the safety, wellbeing, and quality of life of Veterans, their romantic partners, and their families. However, treatments that address co-occurring PTSD-AUD and restore Veterans' psychosocial functioning are lacking. The overall goal of this project is to improve treatment approaches aimed at reducing symptoms of co-occurring PTSD-AUD and improving functioning among Veterans and their partners. We plan to do this by learning from Veterans, family members, and treatment providers in order to inform an adaptation of a brief dyadic AUD intervention to be delivered alongside integrated PTSD-AUD treatment for Veteran couples and then conducting a pilot trial of an adapted Brief Family Involved Treatment (B-FIT) intervention with Veterans with PTSD-AUD and their romantic partners.